Skip to content
Ontario Rheumatology Association
  • Login
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • Informatics
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory
  • Login
  • About
    • Overview
    • Organizational Priorities and Committees
    • Leadership
    • Annual Awards
  • Events
  • EAP & Limited Use Codes
    • Overview
    • Exceptional Access Program
    • EAP Forms and Downloads
    • Limited Use Codes
    • Biosimilar Fact Sheet
    • NIHB Drug List
    • MOHLTC IVIG Request Form
  • Informatics
    • Rheumatology EMR Database at ICES
  • Members
    • Overview
    • Member Directory
    • Peer Mentor Forum
    • Resource for Members
    • Become A Member
    • Renew Membership
    • Membership Perks
  • News
    • Overview
    • Drug Shortages Info
    • Newsletters
    • Other Publications
    • Info Hub
  • Contact
  • Directory

Announcing the Retirement of Denis Morrice, ORA Executive Director

Denis Morrice • Edition: Fall 2020
  • This is my last one!

ORA must pay attention to Canada’s medication system since it is acknowledged that drugs are right up there in importance with Doctors and Hospitals.

Well, the Throne Speech noted more talk on the potential introduction of a National Pharmacare Program as recommended in the 1997 National Forum on Health followed by senate committee reports etc., etc.

Drug costs are still an issue and the Feds would like to follow the late John Turner’s success in lowering drug costs. However, PMPRB has come under great criticism and pressure from IMC and others with the concern that new drugs will not be launched or greatly delayed in Canada due to restrictions on pricing.

Further, President Trump’s Importation initiative of Canadian drugs will result in serious and quick drug shortages in Canada. Health Canada and the Multi-Stakeholder Steering Committee on Drug Shortages are doing their best to address this inappropriate initiative. The US should deal with their drug costs like every other industrialized country.

The pCPA has brought about great cooperation and collaboration among the provincial and territorial drug programs.

The proposed introduction of a Drug Agency would hopefully align the various activities of Health Canada, CADTH, PMPRB and pCPA and all their various internal committees.

An incredible amount is happening with the ORA Board and their committees and I suggest that every member simply review the Sept 17 ORA Board agenda to get an appreciation of the amount of work being done by your colleagues.

As I leave the ORA as your Executive Director I can assure you that it has been a real honour to work with so many of you that are unbelievably patient focussed. Having worked with and engaged with a number of medical associations it is my observation that the ORA is the most progressive and action oriented Medical Association in Canada. The ORA Board and Committee members confront issues that impact patients and take the time to stick handle them to a successful conclusion. It takes relationship building and staying at the table. Things don’t just happen – people make them happen and that’s what ORA members do. The ORA clearly operates under the banner of “doing the right thing for the right reasons”.

For anyone wishing to extend their well wishes to Denis, his email address remains unchanged (or contact Sandy Kennedy!)

Other Articles in the Fall 2020 Newsletter

  • President's Message
  • OMA Section on Rheumatology Report
  • Government Affairs
  • News From Ottawa: Recent Practice Announcements
  • 2021 Membership Renewals Now Open!
  • Northern Ontario Committee
  • Communications Update
  • MoH Announcement:Transition to Publicly Funded Shingrix® Vaccine for Ontario’s Shingles Immunization Program (For Patients 65-70 Years of Age)
Editions
  • Winter 2021
  • Fall 2020
  • Summer 2020
  • Winter 2020
  • Winter 2019
  • Fall 2019
  • Spring 2019
  • Winter 2018
  • Fall 2018
  • Summer 2018
  • Summer 2017
  • Spring 2017
  • Fall 2017
  • Archive
  • Meet the Speakers: ORA 20th Annual Scientific Meeting
Committees
Communications Informatics Models of Care OMA
Tags
Biosimilar CSDTH Models of Care OBRI OMA pCPA SADIE

Contributors

The ORA’s executive members are the core contributors to the newsletter. The ORA welcomes guest contributions to the newsletter from members-at-large and others in the rheumatology community.

Contributors
Ontario Rheumatology Association

© 2020 Ontario Rheumatology Association. All Rights Reserved. Website by Digital Chaos Inc.

  • About
  • Annual Awards
  • Events
  • EAP & Limited Use Codes
  • Exceptional Access Program
  • EAP Forms and Downloads
  • Limited Use Codes
  • Biosimilar Fact Sheet
  • NIHB Drug List
  • MOHLTC IVIG Request Form
  • Informatics
  • Members
  • Member Directory
  • Past Meeting Resources
  • Peer Mentor Forum
  • BecomeA Member
  • Renew Membership
  • News
  • Newsletters
  • Drug Shortages Info
  • Other Publications
  • Info Hub
  • Contact
  • Privacy